Health Through Evidence (HTE) was pleased to participate in ISPOR Europe 2026, held on 8โ11 November 2026 in Vienna, Austria, presenting nine research posters spanning a broad range of topics in Health Economics and Outcomes Research (HEOR).
Our contributions reflected our ongoing commitment to generating evidence that supports informed healthcare decision-making, bringing together economic evaluations, real-world evidence, patient-centred research, healthcare financing, and innovative analytical methodologies.
Our research contributions at ISPOR Europe 2026 included:
1. Out-of-Pocket Costs and Financial Burden of Duchenne Muscular Dystrophy in Greece: A Cross-Sectional Study
Authors: E. Katsomiti, C. Kastanioti, G. Mavridoglou, C. Tzanetakos, G. Gourzoulidis
2.ย Knowledge, Attitudes, and Determinants of Respiratory Syncytial Virus Vaccination Among Physicians and Older Adults in Greece: A Cross-Sectional Online Survey
Authors: K. Baran, M. Peppa, K. Syrigos, G. Gourzoulidis
3. Cost-Effectiveness Analysis of Liposomal Irinotecan in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin (NALIRIFOX) for the First-Line Treatment of Adult Patients With Metastatic Adenocarcinoma of the Pancreas in Greece
Authors: G. Gourzoulidis, V. Chotzagiannoglou, A. Angelopoulou, E. Solakidou, C. Tzanetakos
4. Real-World Persistence and Switching Patterns Among First-Line Aromatase Inhibitors in Postmenopausal Breast Cancer in Greece: Evidence From the National E-Prescription Database (2020โ2022)
Authors: G. Gourzoulidis, C. Kastanioti, G. Mavridoglou, T. Kotsilieris, A. Tsolakidis, K. Mathioudakis, E. Fotiadou, C. Makri, C. Tzanetakos
5. From Pay-as-You-Go to Actuarial Resilience: Modeling the Fiscal Sustainability of Greek Healthcare Financing, 2024โ2050
Authors: G. Mavridoglou, G. Gourzoulidis
6. Economic Impact of Talazoparib Adoption in Germline BRCA1/2-Mutated HER2-Negative Advanced Breast Cancer: A Budget Impact Analysis for Greece
Authors: S. Tzorou, M. Peppa, K. Syrigos, G. Gourzoulidis
7. Real-World Economic Analysis of Fixed-Duration Venetoclax-Based Versus Continuous BTKi Therapy in First-Line Chronic Lymphocytic Leukemia in Greece
Authors: C. Tzanetakos, G. Papageorgiou, A. Kollia, A. Draganigos, T. Vlachopiotis, G. Gourzoulidis
8. Liposomal Irinotecan in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin (NALIRIFOX) for the First-Line Treatment of Adult Patients With Metastatic Adenocarcinoma of the Pancreas. A Budget Impact Analysis in Greece
Authors: V. Chotzagiannoglou, A. Angelopoulou, E. Solakidou, C. Tzanetakos, G. Gourzoulidis
9. Causal Machine Learning for Health Insurance Coverage Effects: From Individual Treatment Effect Estimation to Policy Optimization Using Real-World Data
Authors: N. Kiriakidou, I. E. Livieris, T. Kotsilieris, C. Tzanetakos, G. Gourzoulidis
Beyond presenting our research, ISPOR Europe 2026 provided a valuable opportunity to engage with the international HEOR community, exchange scientific perspectives, reconnect with colleagues and collaborators, and discuss emerging approaches to evidence generation and healthcare decision-making.
We extend our sincere thanks to everyone who visited our posters and contributed to the discussions throughout the congress.
Special thanks to our research team, co-authors, and collaborators for their dedication and valuable contributions to the work presented in Vienna.
At Health Through Evidence, we remain committed to advancing rigorous, relevant, and decision-focused research that contributes to more informed and sustainable healthcare decisions.
